FDA Requires Vision Loss Warning on Popular GLP-1 Medications
The US Food and Drug Administration has found evidence linking popular GLP-1 medications to a potential risk of a rare eye condition. Consequently, the agency has ordered manufacturers to add a blindness risk warning label to these weight management and diabetes drugs.
Makers of popular weight loss and diabetes medications, including Wegovy, Zepbound, and Ozempic, will soon be required to update their product labeling. The US Food and Drug Administration announced the decision after finding evidence of a potential increased risk of a rare eye condition associated with these drugs.
According to the reports, this rare eye condition carries the risk of causing blindness and vision loss. While some reports state that the agency has found evidence of a potential increased risk linked to the use of GLP-1 drugs for weight management and diabetes, others specify that the companies making these treatments have been directly ordered to add the warning label.
The regulatory action impacts widely used medications in the GLP-1 category. Affected companies must now include the blindness risk warning on their products, though further details on the implementation timeline were not provided in the current reports.
Turkrazzi roundup · from 4 sources
What the sources say
-
Ars Technica · 2 h ago
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
-
The Guardian · 4 h agoPharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
-
CNBC · 9 h ago
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
-
Sky News · 17 h agoFDA orders blindness risk warning on weight loss drugs